Literature DB >> 3132761

Natural history of multiple intrahepatic canine islet allografts during and following administration of cyclosporine.

R Alejandro1, Z Latif, K S Polonsky, F L Shienvold, F Civantos, D H Mint.   

Abstract

Cyclosporine (CsA) prevented acute rejection of intrahepatic canine islet allografts (IHIA) in 5/5 pancreatectomized dogs. Normal fasting blood glucose levels were sustained in these dogs for 210 +/- 78 days (mean +/- SEM) following withdrawal of CsA. We tested whether combining islets from more than one pancreas would improve function and prolong islet allograft survival during and following administration of CsA. Areas under the glucose disappearance (GDA) and C-peptide response (CPA) curves following i.v. glucose (0.5 g/kg), 1 month posttransplant were not significantly different using islets from 1 or 2 pancreases, whereas GDA and CPA approached normal if islet yields from 3 or more pancreases were combined. Mean islet allograft survival following interruption of CsA decreased with an increase in the number of donor pancreases (one: 210 +/- 78 days, vs. two: 113 +/- 23 days, vs. greater than 2: 57 +/- 5 days). These studies demonstrate that: (1) IHIA uniformly resulted in fasting euglycemia in 36 of 38 diabetic dogs treated with CsA; (2) normal i.v. glucose metabolism required the combined islet yield of 3 or more donor pancreases, suggesting that a substantial number of intrahepatic islet cells are functionally lost despite effective CsA-induced immunosuppression; (3) use of multiple donors to accumulate an increased mass of islets may immunologically compromise allograft survival following discontinuation of CsA (these experiments, however, do not exclude a direct relationship between the duration of CsA therapy and the duration of immune unresponsiveness following interruption of CsA in multidonor islet allografts as an independent variable); and (4) unmodified islets obtained from multiple donors seem to require continuous immunosuppression to prevent rejection.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3132761     DOI: 10.1097/00007890-198806000-00008

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  7 in total

1.  25 YEARS OF THE RICORDI AUTOMATED METHOD FOR ISLET ISOLATION.

Authors:  Lorenzo Piemonti; Antonello Pileggi
Journal:  CellR4 Repair Replace Regen Reprogram       Date:  2013

Review 2.  Pancreatic and islet transplantation.

Authors:  L Rosenberg
Journal:  Curr Gastroenterol Rep       Date:  2000-04

Review 3.  Clinical islet cell transplantation. Are we there yet?

Authors:  L Rosenberg
Journal:  Int J Pancreatol       Date:  1998-12

Review 4.  Treatment of diabetes mellitus.

Authors:  R P Robertson; D J Klein
Journal:  Diabetologia       Date:  1992-12       Impact factor: 10.122

5.  Clinical studies of human islet transplantation.

Authors:  N J London
Journal:  Ann R Coll Surg Engl       Date:  1995-07       Impact factor: 1.891

6.  Pancreatic islet transplantation after upper abdominal exenteration and liver replacement.

Authors:  A G Tzakis; C Ricordi; R Alejandro; Y Zeng; J J Fung; S Todo; A J Demetris; D H Mintz; T E Starzl
Journal:  Lancet       Date:  1990-08-18       Impact factor: 79.321

7.  Interim report on the effective intraperitoneal therapy of insulin-dependent diabetes mellitus in pet dogs using "Neo-Islets," aggregates of adipose stem and pancreatic islet cells (INAD 012-776).

Authors:  Anna Gooch; Ping Zhang; Zhuma Hu; Natasha Loy Son; Nicole Avila; Julie Fischer; Gregory Roberts; Rance Sellon; Christof Westenfelder
Journal:  PLoS One       Date:  2019-09-19       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.